Hot Products
0102030405
China Suppliers Factory Benfotiamine - High Bioavailability Lipid-Soluble Vitamin B1 for Superior Health Benefits
C19H23N4O6PS
Description
As a synthetic derivative of vitamin B1 (thiamine), benfotiamine significantly surpasses ordinary vitamin B1 in bioavailability, targeting and clinical efficacy through structural optimization and pharmacokinetic improvement.
1. Structural Innovation: Lipid-Soluble Modification
Ordinary vitamin B1 (thiamine) is a water-soluble molecule that relies on intestinal sodium-dependent carriers (ThTr1/2) for active transport. It has a low absorption rate (<5%) and is easily saturated. Benfotiamine is converted into a lipid-soluble prodrug by introducing benzoyl and phosphate groups (structural formula C19H23N4O6PS), which can bypass carrier restrictions and directly penetrate intestinal mucosal cells through passive diffusion. The absorption efficiency is increased to more than 80%, and the bioavailability is 3-5 times that of ordinary B1.
2. Pharmacokinetic Advantages: Long-term Effect and Tissue Targeting
Ordinary B1 has a short half-life in the blood (about 3.5 hours) and is easily cleared quickly by the kidneys. Benfotiamine is hydrolyzed into active thiamine by phosphatase in the body and further converted into thiamine pyrophosphate (TPP). Its lipid solubility makes it easier to accumulate in the phospholipid layer of the cell membrane, prolonging the duration of action (half-life > 6 hours). Its ability to penetrate the blood-brain barrier and nerve sheath is 8-10 times that of ordinary B1, effectively acting on the central and peripheral nervous systems.
3. Metabolic Regulation: Multi-target Inhibition
In a hyperglycemic environment, benfotiamine shows unique advantages through the following mechanisms:
Blocking AGEs generation: Inhibiting hexosamine and polyol pathways, reducing advanced glycation end products (AGEs) accumulation.
Anti-inflammatory and antioxidant: Downregulating NF-κB and TXNIP/NLRP3 inflammasomes, reducing IL-6 and TNF-α.
Mitochondrial protection: Restoring pyruvate dehydrogenase complex (PDH) function and reducing lactic acid accumulation.
4. Clinical Efficacy: High-dose Tolerance and Deep Repair
Benfotiamine can stably increase tissue TPP concentration within the dose range of 150-600 mg/day. Clinical trials have shown significant improvement in nerve conduction velocity (+2.1 m/s vs placebo) and pain scores (VAS reduced by 40%), with no reported liver or kidney toxicity.
5. Stability and Compatibility of Preparations
Benfotiamine is significantly more stable than ordinary B1 in acidic environments (pH 2.0-4.0), with a degradation rate of less than 5%. Its lipid-soluble properties support advanced delivery systems such as nanoemulsions and liposomes for targeted delivery.
Frequently Asked Questions
Q1: What is the main difference between Benfotiamine and Vitamin B1?
Benfotiamine is a lipid-soluble derivative, while Vitamin B1 is water-soluble. This allows Benfotiamine to have much higher bioavailability (up to 80%) and better tissue penetration.
Q2: How does Benfotiamine help with diabetic neuropathy?
It blocks the pathways that lead to the formation of Advanced Glycation End products (AGEs), which are primary drivers of nerve damage in high-glucose environments.
Q3: Is Benfotiamine safe for long-term use?
Yes, clinical trials have shown that Benfotiamine is well-tolerated at doses of 150-600 mg/day with no significant reports of liver or kidney toxicity.
Q4: Can Benfotiamine cross the blood-brain barrier?
Yes, its lipid solubility allows it to penetrate the blood-brain barrier and nerve sheaths 8-10 times more effectively than standard Vitamin B1.
Q5: Why is Benfotiamine preferred in pharmaceutical preparations?
It is highly stable in acidic environments (pH 2.0-4.0) and compatible with various multivitamins, making it ideal for oral supplements and complex drug formulations.
Q6: What are the antioxidant benefits of Benfotiamine?
It enhances glutathione reductase activity and downregulates inflammatory factors like NF-κB, effectively reducing oxidative stress at the cellular level.